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Abstract: Mass spectrometry-based analyses are essential tools in the ﬁ  eld of biomarker research. However, detection and 
characterization of plasma low abundance and/or low molecular weight peptides is challenged by the presence of highly 
abundant proteins, salts and lipids. Numerous strategies have already been tested to reduce the complexity of plasma 
samples. The aim of this study was to enrich the low molecular weight fraction of rat plasma. To this end, we developed 
and compared simple protocols based on membrane ﬁ  ltration, solid phase extraction, and a combination of both. As assessed 
by UV absorbance, an albumin depletion  99% was obtained. The multistep fractionation strategy (including reverse 
phase HPLC) allowed detection, in a reproducible manner (CV   30%–35%), of more than 450 peaks below 3000 Da by 
MALDI-TOF/MS. A MALDI-TOF/MS-determined LOD as low as 1 fmol/µL was obtained, thus allowing nanoLC-Chip/
MS/MS identiﬁ  cation of spiked peptides representing ∼10
–6% of total proteins, by weight. Signal peptide recovery ranged 
between 5%–100% according to the spiked peptide considered. Tens of peptide sequence tags from endogenous plasma 
peptides were also obtained and high conﬁ  dence identiﬁ  cations of low abundance ﬁ  brinopeptide A and B are reported here 
to show the efﬁ  ciency of the protocol. It is concluded that the fractionation protocol presented would be of particular inter-
est for future differential (high throughput) analyses of the plasma low molecular weight fraction.
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1. Introduction
A biomarker can be deﬁ  ned as a detectable change in a given biological system that conveys informa-
tion about biological state. Biomarkers then group together molecules whose levels can be used as 
indicators of a particular disease state and/or help get further insights in the molecular mechanisms 
potentially involved in various pathophysiological processes. Proteins and peptides are of paramount 
importance for most of the physiological processes. With the recent advances in mass spectrometry 
techniques for protein and peptide analysis, proteomic and peptidomic analyses have naturally emerged 
as essential tools in the ﬁ  eld of biomarker research. In this framework, plasma or serum are being 
referred as the most valuable samples for biomarker discoveries. However, detection and characteriza-
tion of low abundance and/or low molecular weight plasma peptides is challenged by the presence of 
highly abundant proteins, salts and lipids (Adkins, 2002). Therefore, reduction of the complexity of 
plasma samples must be considered as a step that is impossible to circumvent prior to mass spectrometry-
based analyses.
At present various approaches are being used ranging from high abundance protein removal to a 
host of fractionation methods. High abundance protein removal is generally performed with the use of 
antibody-based or afﬁ  nity dye-based resins (Adkins, 2002; Govorukhina, 2003; Greenough, 2004; 
Fountoulakis, 2004; Colantonio, 2005; Granger, 2005; Björhall, 2005; Martosella, 2005; Brand, 2006), 
membrane ﬁ  ltration (Tirumalai, 2003; Chernokalskaya, 2004; Tammen, 2005b; Tanaka, 2006; Orvisky, 
2006; Ingvarsson, 2006; Zheng, 2006), and protein precipitation procedures (Merrell, 2004; Chen, 2005; 
Colantonio, 2005). Fractionation methods combine different separation techniques including electro-
phoretic (Righetti, 2005) and chromatographic (Lescuyer, 2004; Linke, 2004; Baumann, 2005). Among 386
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peptide extraction techniques, solid phase extrac-
tion (SPE) also represents an attractive approach 
(Souverain, 2004; Koomen, 2005). In the above 
mentioned studies, analyses of the plasma proteome 
have often combined multidimensional peptide 
separation strategies. Loss of proteins and peptides 
of interest dramatically increases as the number of 
sample preparation steps is increased. Therefore, 
cautions have to be considered regarding limited 
resin capacity, lack of speciﬁ  city of afﬁ  nity-based 
methods and binding of low abundance species to 
high abundance proteins that results in removal of 
potential biomarker candidates, including hor-
mones, lipoproteins and cytokines (Schussler, 2000; 
Dea, 2002; Granger, 2005). Moreover, even after 
depletion, the remaining proteins can still be suf-
ficiently abundant to hamper low-abundance 
protein biomarker determination. Despite these 
drawbacks, removal of abundant molecules and/or 
sample fractionation made MS analyses and/or 
identiﬁ  cation of potential biomarkers possible in 
most cases (Adkins, 2002; Tirumalai, 2003; Aldred, 
2004; Tammen, 2005b; Tanaka, 2006).
The aim of this study was to develop a simple 
protocol to avoid excess loss of material. Such a 
protocol was expected to allow efﬁ  cient separation 
of low and high abundance molecules from a 
complex mixture, and suitable for high throughput 
peptidomics. Rat plasma fractionation was per-
formed using various methodologies based on 
membrane ﬁ  ltration, SPE or a combination of both. 
Evaluation and comparison of these protocols were 
performed by determination of total protein con-
centration, SDS-PAGE analysis, and estimation of 
albumin depletion by UV absorbance. MALDI-
TOF/MS analyses of fractionated samples were 
also compared, with determination of the number 
of peaks detected and of reproducibility of the 
experiments. Spiking of crude plasma and of frac-
tionated samples with standard peptides were also 
performed to determine limit of detection (LOD) 
and signal recovery of spiked peptides. Finally, 
peptide identifications were performed with a 
nanoLC-Chip/MS/MS system.
2. Materials and Methods
2.1. Materials
Potassium-EDTA vacutainer
TM tubes were pur-
chased from Becton, Dickinson (Le Pont de Claix, 
France). All buffers were prepared with Milli-Q
®
water (Millipore, Milford, MA, U.S.A.). Vivaspin
® 
2 30,000 MWCO centrifugal devices were obtained 
from Sartorius (Palaiseau, France). The Oasis
® 
HLB (Hydrophilic Lipophilic Balance) 96-well 
extraction plates were obtained from Waters 
(Milford, MA, U.S.A.). Acetonitrile (HPLC grade) 
was purchased from Carlo Erba (Val de Reuil, 
France). The BCA protein assay kit was obtained 
from Pierce Biotechnology (Rockford, IL, U.S.A.). 
Quantified standard mixtures of peptides and 
proteins were purchased from Bruker Daltonics 
Gmbh (Bremen, Germany). All other reagents and 
chemicals were purchased from Sigma Diagnostics 
(St. Louis, MO, U.S.A.).
2.2. Animals and biological samples
Fifteen male Sprague Dawley rats (Janvier CERJ, 
Le Genest-St-lsle, France) were housed individu-
ally in a temperature-controlled room (25 ± 1 °C), 
with constant photoperiod (12/12, light/dark). They 
were given free access to water and to a standard 
diet (50% carbohydrate, 5% fat, and 24% protein, 
in mass percentage), and allowed to acclimatize 
for several days. The rats were maintained and 
treated according to the local Ethics Committee 
and CNRS (Centre National de la Recherche Sci-
entiﬁ  que) guidelines for the care and use of labora-
tory animals.
When the rats reached 439.9 ± 2.8 g, blood 
samples were collected into potassium-EDTA 
vacutainer
TM tubes and plasma were prepared 
through a standardized protocol. After withdrawal, 
whole blood samples were centrifuged for 10 min 
at 4 °C and at 3000 rpm (swing bucket rotor) to 
perform a ﬁ  rst separation of plasma from blood 
cells. Plasma was then centrifuged again for 10 min 
at 10000 rpm (ﬁ  xed angle rotor) to remove any 
residual cells (like platelets), particulates and/or 
lipids. The ﬁ  fteen plasma samples were then pooled 
and aliquots were stored at –80 °C.
2.3. Plasma sample preparation
Three protocols of plasma sample preparation were 
compared (Fig. 1). All experiments were conducted 
in duplicate.
In the ﬁ  rst protocol (SPE), 500 µL of pooled 
plasma samples were diluted in an equal volume of 
50 mM aqueous acetic acid and incubated for 15 
min at room temperature. Each well was pre-
conditioned with 1 mL of acetonitrile, followed by 
1 mL of 50 mM aqueous acetic acid. As the binding 387
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capacity of the phase contained in a well is limited 
(20 µg of protein per mg of phase sorbent), each 
diluted sample was equally distributed to four wells 
of an Oasis
® HLB extraction plate to limit over-
charge. Samples were pulled through the plate using 
a vacuum pump. The plate was then washed with 1 
mL of a 50 mM aqueous acetic acid solution that 
contained 5% (v/v) acetonitrile. Elution was per-
formed with 200 µl of a 50 mM aqueous acetic acid 
solution that contained 50% (v/v) acetonitrile. The 
four eluates of a same sample were then pooled and 
0.5 µL of the resulting solutions were spotted on a 
stainless steel MALDI target plate (Sample Plate 
384; Bruker Daltonics Gmbh, Bremen, Germany).
In the second protocol (UF), 500 µL of pooled 
plasma samples were diluted in 1500 µL of water 
that contained 10% (v/v) acetonitrile, and then 
incubated at room temperature for 30 min. Ultra-
ﬁ  ltration membranes were conditioned with 1 mL 
of water and then 2 mL of water that contained 
7.5% (v/v) acetonitrile. Samples were transferred 
to centrifugal devices and centrifuged for 60 min 
at 6000 rpm (ﬁ  xed angle rotor) in order to deplete 
high molecular weight proteins. 0.5 µL of the 
resulting ﬁ  ltrates were spotted on a stainless steel 
MALDI target plate.
In the third protocol (UF-SPE), 500 µL of 
pooled plasma samples were also prepared using 
Vivaspin
® 2 centrifugal devices as described above. 
The ﬁ  ltrates were further fractionated using Oasis
® 
HLB extraction plates as described above, except 
that diluted ﬁ  ltrates were applied to only one well 
of an Oasis
® HLB extraction plate due to their 
lower protein concentration compared to plasma. 
0.5 µL of eluates were spotted on a stainless steel 
MALDI target plate.
For all three protocols, total protein concentra-
tion of prefractionated samples was determined 
using a BCA protein assay kit and 20 µg of proteins 
were subjected to SDS-PAGE analysis (Fig. 1).
2.4. 1-D SDS-PAGE
SDS-PAGE analyses were carried out using 15% 
SDS polyacrylamide gels in a MiniProtean 3 cell 
(Biorad, Hercules, CA, U.S.A.). After denaturation 
by boiling for 5 min, 20 µg of proteins were applied 
per lane and electrophoresed for 60 min at 140 V. 
The gels were stained O/N with Phastgel™ Blue 
R (Pharmacia Biotech AB, Uppsala, Sweden). 
After 3 washings, gel images were acquired with 
a GS800 calibrated densitometer (Biorad). The 
albumin bands were determined by comparison to 
6.5–205-kDa molecular weight marker.
2.5. Albumin depletion capacity
Albumin depletion capacity of the three protocols 
of plasma sample preparation were estimated and 
compared (Fig. 1). Aqueous HSA solutions (1, 2, 
10, 20, 40, 100, and 200 µg/mL) were prepared in 
order to construct calibration curves. Samples were 
prepared as follows: three dilutions (1:500, 1:400, 
and 1:250) of crude plasma in water; two dilutions 
(1:100, and 1:200) of SPE eluates in water; speed-
vac concentration of UF ﬁ  ltrates (5- and 10-fold) 
and of UF-SPE eluates (2.5- and 3-fold).
Relative quantitation was performed by UV 
absorbance measurement using an Agilent 1100 
series liquid chromatograph equipped with an 
UV-vis detector, the whole HPLC system being 
controlled by the ChemStation Rev A10.02 software 
(Wilmington, DE, U.S.A.). 50 µl of aqueous HSA 
solutions and of the samples (diluted plasma, diluted 
SPE eluates, and concentrated UF ﬁ  ltrates and UF-
SPE eluates) were injected onto the LC reverse-
phase column (Vydac 300-C8, 25 cm × 2.1 mm, 
with a 5 µm particle size). The procedure was con-
ducted in duplicate for each concentration. Mobile 
phase solvents were water (A) and acetonitrile (B), 
containing 0.1% and 0.08% TFA, respectively. The 
chromatographic separation was achieved with the 
following gradient: 2 min. at 10% B; from 10% to 
65% B in 33 min.; from 65% to 90% B in 5 min. 
finally, 5 min. at 90% B. The column was 
maintained at 40 °C and the ﬂ  ow rate was set at 
250 µl.min. UV absorbance detection was set at 
214 nm.
Integration of the peak corresponding to albu-
min was performed using the ChemStation Rev 
A10.02 software. Linear regression analysis was 
used to define calibration curves. Regression 
analysis was performed using the equation 
y = ax + b, which was ﬁ  tted to the data, where y 
represents the albumin area, x the albumin injected 
quantity, a the slope of the regression line and b 
the y-intercept.
2.6. MALDI-TOF/MS analyses
Deposition of 0.5 µL of each sample (see 2.3. and 
Fig. 1) on stainless steel MALDI target plates was 
followed by addition of 0.5 µl of a saturated solution 
of α-cyano-4-hydroxycinnamic acid. Each sample 
was spotted in quadruplicate. MALDI spectra were 388
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obtained using an ULTRAFLEX™ mass spectrometer 
(Bruker Daltonics Gmbh, Bremen, Germany). The 
instrument was used at a maximum accelerating 
potential of 25 kV in positive mode, and spectra were 
acquired both in the reﬂ  ector and linear modes.
In reﬂ  ector mode, external mass calibration was 
performed using a commercially prepared standard 
mixture of peptides (Bruker Daltonics Gmbh, 
Bremen, Germany). This calibration of MALDI 
mass spectra was carried out using singly charged 
monoisotopic peaks of angiotensin II (m/z = 
1046.542), angiotensin I (m/z = 1296.685), 
substance P (m/z = 1347.736), bombesin (m/z = 
1619.823), ACTH1–17 (m/z = 2093.087) and 
ACTH18–39 (m/z = 2465.199), and somatostatin 
(m/z = 3147.471). For each MALDI analysis, 400 
spectra were acquired (100 laser shots, at a laser 
power of 40 ± 5%, at four different spot positions) 
using the FlexControl™ acquisition software 
(Version 2.2, Bruker Daltonics). Monoisotopic 
peptide masses of signals with a signal-to-noise 
ratio  3 in a mass range of 700–4000 Da were 
automatically annotated using the FlexAnalysis 
software (Version 2.2, Bruker Daltonics).
In linear mode, external mass calibration was 
performed using a commercially prepared standard 
mixture of peptides and proteins (Bruker Daltonics 
Gmbh, Bremen, Germany). This calibration of 
MALDI mass spectra was carried out using singly 
charged average peaks of angiotensin II (m/z = 
1047.20), angiotensin I (m/z = 1297.51), substance 
P (m/z = 1348.66), bombesin (m/z = 1620.88), 
ACTH1–17 (m/z = 2094.46), ACTH18–39 (m/z = 
2466.73), somatostatin 28 (m/z = 3149.61), insulin 
Rat plasma
500 µL 
SPE UF UF-SPE 
Prot. Assay  
+ SDS-PAGE  
+ UV absorbance of the albumin peak
+ MALDI-TOF/MS
S2 
MicroLC and 
microcollect
500 µL 
500 µL 
LOD determination 
+ Signal recovery 
MALDI-TOF/MS 
of each fraction 
nanoLC-
Chip/MS/MS 
Endogenous plasma 
peptides identification
500 µL 
500 µL 
S1 
Figure 1. Flowchart of plasma sample preparation and analyses. Three protocols were used to fractionate 500 µL of rat plasma. The SPE 
protocol was performed using Oasis
® HLB 96-well extraction plates; the UF protocol was performed using Vivaspin
® 2 30,000 MWCO cen-
trifugal devices; the UF-SPE protocol was a combination of the SPE and UF protocols. Total protein concentration, SDS-PAGE analysis, 
estimation of albumin depletion by UV absorbance and MALDI-TOF/MS were determined to compare crude plasma samples to SPE eluates, 
UF ﬁ  ltrates, and UF-SPE eluates. In a separate experiment, we performed LOD determinations and peptide signal recovery in plasma 
samples using the UF-SPE protocol followed by microLC fractionation by spiking crude plasma (S1) and UF-SPE eluates (S2) with standard 
peptides. To this end, UF-SPE eluates were further fractionated using a capillary LC system (equipped with a micro fraction collector). Each 
fraction was then analyzed by MALDI-TOF/MS, and by nanoLC-Chip/MS/MS to identify and characterize endogenous plasma peptides.389
Plasma peptidomics
Biomarker Insights 2007:2
(m/z = 5734.56), ubiquitin I (m/z = 8565.89), 
cytochrom C (m/z = 12361.55), and doubly charged 
average peak of cytochrom C (m/z = 6181.05). For 
each MALDI analysis, 600 spectra were acquired 
(200 laser shots, at a laser power of 60 ± 5%, at 
three different spot positions) using the FlexCon-
trol™ acquisition software. After baseline subtrac-
tion, all signals with a signal-to-noise ratio  20 in 
a mass range of 1000–15000 Da were automati-
cally annotated using the FlexAnalysis software.
For a given sample, reproducibility of the 4 
repeated spots was assessed by calculating the 
coefﬁ  cient of variation (CV) of all peak intensities 
normalized by global intensity of the correspond-
ing spectrum. Subsequently, reproducibility of 
duplicate experiments was assessed by calculating 
the CV of averaged intensities of the peaks, calcu-
lated for each single experiment. The number of 
peaks detected in each sample was computed.
2.7. MicroLC fractionation
UF-SPE eluates were speed-vac concentrated to 
10 µL, and then fractionated using a capillary LC 
system equipped with a micro fraction collector 
(Fig. 1), all the system being controlled by the Chem-
Station Rev A10.02 software (Agilent 1100 series, 
Wilmington, DE, U.S.A.). The samples were injected 
onto a LC reverse-phase column (Zorbax 300SB-
C18, 15 cm × 500 µm, with a 5 µm particle size). The 
procedure was conducted in duplicate for each con-
centration. Mobile phase solvents were water (A) and 
acetonitrile (B), containing 0.05% and 0.045% TFA, 
respectively. The chromatographic separation was 
achieved with the following gradient: 5 min. at 10% 
B; from 15% to 60% B in 35 min.; from 60% to 80% 
B in 5 min. ﬁ  nally, 5 min. at 80% B. The column was 
maintained at 40 °C and the ﬂ  ow rate was set at 
16 µl.min
–1. Between 2 and 40 min., fractions of 
2 min. each were collected in a 96 microwell plate.
Each collected fraction was speed-vac concen-
trated to 10 µL, and 0.5 µL of the resulting solutions 
were spotted on a MALDI target and analyzed to 
follow the peak elution and to specify the fractions 
containing the spiked peptides. Signal positions of 
standard peptides (retention time) were determined 
in control experiments without plasma.
2.8. LOD determination
It is well known that sample preparation steps gen-
erally induce loss of peptides. Knowing that 50 fmol 
of a given peptide can easily be detected by 
MALDI-TOF/MS, and estimating arbitrarily and 
pessimistically that the remaining quantity of a 
given molecule after the UF-SPE protocol is ten 
times lower than the initial spiked quantity, we 
decided to spike plasma samples (500 µL) with 
500–10000 fmol (representing approximately 
10
–4–10
–6% of total proteins, by weight) of a stand-
ard mixture of peptides. The main requirements for 
such a mixture were to know exactly the concentra-
tion of composing peptides, which also had to be in 
a mass range representative of endogenous plasma 
peptides (1000–3000 m/z). For these reasons, we 
used the peptide standards provided by Bruker 
Daltonics (see above). We performed LOD deter-
minations of spiked peptides in plasma samples 
using the UF-SPE protocol followed by microLC 
fractionation (Fig. 1). Peptides were spiked 
1) directly in crude plasma before its entering in the 
UF-SPE protocol (S1, see Fig.1), and 2) in UF-SPE 
eluates (S2, see Fig. 1). The procedure was con-
ducted in duplicate for each concentration. LOD 
determination was based on detection of a given 
peptide on MALDI mass spectra. An estimation of 
peptide signal recovery was also obtained by com-
paring peak intensities between S1 and S2.
2.9. NanoLC-Chip/MS and MS/MS
NanoLC-Chip/MS and MS/MS of the peptides 
contained in microLC fractions collected from 
UF-SPE eluates were performed (Fig. 1) on an 
Agilent 1100 Series HPLC-Chip/MS system 
(Agilent Technologies, Palo Alto, U.S.A.) coupled 
to a HCT™ Ultra ion trap (Bruker Daltonics Gmbh, 
Bremen, Germany).
The chromatographic separations of the 
microLC collected fractions were conducted on an 
HPLC chip composed of a 40 nL enrichment col-
umn and a reverse-phase separation column 
(Zorbax 300SB-C18, 15 cm × 75 µm, with a 5 µm 
particle size). Mobile phase solvents were water 
(A) containing 2% acetonitrile and 0.1% HCOOH 
and acetonitrile (B) containing 2% water and 0.1% 
HCOOH. The chromatographic separation was 
achieved with the following gradient: from 8% to 
40% B in 30 min. from 40% to 70% B in 1 min. 
ﬁ  nally, 3 min. at 70% B and the ﬂ  ow rate was set 
at 300 nl.min
–1.
The mass spectrometer was operated in positive 
mode by applying a voltage of −1850 V to the 
capillary cap. The fractions were initially analyzed 
in full scan mode. A total of 4 scans were averaged 390
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to obtain a MS spectrum (scan speed 8100 m/z per 
sec.). Using an automatic switching between MS 
and MS/MS modes, MS/MS fragmentation was 
performed on the three most abundant doubly or 
triply charged ions on each spectrum, using 
collision-induced dissociation. A total of 6 scans 
were averaged to obtain a MS/MS spectrum (scan 
speed 26000 m/z per sec.). The complete system 
was fully controlled by the ChemStation Rev 
B.01.03 (Agilent, Wilmington, DE, U.S.A.) and 
EsquireControl 6.0 (Bruker Daltonics Gmbh, 
Bremen, Germany) softwares.
For all MS/MS experiments, generated frag-
ment peak lists were submitted to a local Mascot 
server (Mascot version 1.9, Matrix Science, 
London, U.K.). The searches were performed 
against the NCBInr database, and Mascot search 
parameters were set as follows: no enzyme was 
selected, taxonomy was restricted to the Rattus, 
oxidation of M, N-term acetylation and N-acetyla-
tion of proteins were set as variable modiﬁ  cations, 
the peptide mass error tolerance was restricted to 
0.25 Da in both MS and MS/MS modes. Automatic 
de novo sequencing was performed using the 
PEAKS Studio 3.0 software (Bioinformatics 
Solutions Inc., Waterloo, Canada) with the same 
parameters used for Mascot search. All deduced 
sequence tags were submitted to the NCBI BLAST 
(http://130.14.29.110/blast/) program to perform 
sequence similarity searches in the available 
databases and thus identify the peptide. The iden-
tiﬁ  cations were validated according to the estab-
lished guidelines for proteomic data publication 
(Carr, 2004; Bradshaw, 2005; Wilkins, 2006).
2.10. Statistical analysis
Values are presented as means ± SEM of 2–4 
determinations per protocol. Student’s t-test was 
used to compare the total protein amount and deple-
tion, and estimated albumin amount and depletion 
(p   0.05).
3. Results and Discussion
3.1. Characterization of the three 
plasma sample preparation protocols
A commercial protein assay kit (BCA) was used 
to determine the concentrations of total proteins in 
crude plasma, UF ﬁ  ltrates and SPE and UF-SPE 
eluates. From these total protein concentrations, 
the total amount of proteins was calculated in crude 
plasma and in prepared samples through the three 
protocols to estimate the loss of total plasma 
proteins. Hence, the protein amount calculated 
after UF, SPE and UF-SPE was signiﬁ  cantly lower 
(2.7-fold, p = 0.0003; 21.9-fold, p   0.0001; and 
235.5-fold, p   0.0001, respectively; Table 1) than 
in crude plasma. Total protein amount was sig-
nificantly reduced by UF compared to SPE 
(8-fold, p = 0.0005), UF-SPE compared to SPE 
(87-fold, p = 0.0003) and UF-SPE compared to UF 
(11-fold, p   0.0001). Total protein depletion from 
plasma samples was then signiﬁ  cantly greater with 
the UF and UF-SPE (1.5–1.6-fold; p   0.0001; 
Table 1) than the SPE protocol, and the combina-
tion of UF and SPE depleted signiﬁ  cantly more 
plasma proteins than UF alone (p   0.0001).
Effectiveness of ultraﬁ  ltration to successfully 
remove high molecular weight proteins is illus-
trated by 1-D SDS-PAGE where bands with a 
molecular weight more than 20,000 Da (lanes 5 
and 6 of the Coomassie blue stained gel, Fig. 2) 
can not be observed. The step of membrane ﬁ  ltra-
tion is then strongly recommended to efﬁ  ciently 
deplete a maximum of high molecular weight 
proteins from plasma. Plasma is believed to be 
composed of more than 10,000 different proteins 
and peptides with a wide range of concentrations 
that spans at least ten orders of magnitude (from 
millimolar to sub-picomolar concentrations). The 
22 major (“high abundance”) proteins occupy 
approximately 99% of the total plasma proteome 
(Anderson and Anderson, 2002), the majority of 
all circulating proteins and peptides being then 
expected to be present at very low concentrations 
(“low abundance”) (Adkins, 2002). Low abun-
dance and/or low molecular weight molecules are 
generally those that are bioactive in physiological 
mechanisms. By depleting more than 99% of 
plasma proteins, our UF and especially UF-SPE 
protocols give the possibility to potentially detect 
low molecular weight proteins and peptides. Con-
sistently, in addition to the depletion of high 
molecular weight proteins, the appearance of low 
molecular weight and/or low abundance proteins 
( 20,000 Da) in the albumin depleted samples by 
the UF and UF-SPE protocols that were not 
detected in the nondepleted plasma demonstrates 
the usefulness and efﬁ  ciency of such depletion 
protocols (lanes 5 and 6 of the Coomassie blue 
stained gel, Fig. 2). Nevertheless, the use of an 
ultraﬁ  ltration step is well known to potentially 391
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remove peptides that are strongly bound to carrier 
proteins, such as albumin. Recovery of peptides 
can notably be improved by denaturating condi-
tions (Tirumalai, 2003; Harper, 2004; Merrell, 
2004). In order to minimize peptide losses, we 
performed the ﬁ  ltration step on diluted plasma 
samples with aqueous acetonitrile (10%), an 
organic solvent that can disrupt hydrophobic inter-
actions. Despite these precautions, some peptide 
losses may remain. In particular, while it was 
present in crude plasma (lane 2 of the Coomassie 
blue stained gel, Fig. 2), the absence of the band 
between 6.5 and 14 kDa in UF ﬁ  ltrates and UF-SPE 
eluates (lanes 5 and 6 of the Coomassie blue stained 
gel, Fig. 2) can be noticed. Further studies should 
aim at reducing such losses in any fractionation 
protocol. On the whole, protein depletion through 
the UF and UF-SPE protocols and SDS–PAGE 
analysis were reproducible between duplicate 
experiments with the appearance of new bands 
below 20,000 Da in the albumin depleted samples. 
Therefore, we believe that these protocols are well-
adapted to explore the plasma low molecular 
weight and/or low abundance fraction.
Albumin generally represents about 50% of 
total plasma proteins (Anderson and Anderson, 
2002). Among others, the presence of such a highly 
concentrated protein is considered as a main obsta-
cle to the detection and characterization of plasma 
peptides. A host of afﬁ  nity-based methods have 
thus been developed to more or less speciﬁ  cally 
remove albumin from plasma samples. The use of 
Cibacron Blue resins generally leads to non-
speciﬁ  c and modest protein removal (Colantonio, 
2005). Albumin depletion kits leads to the deple-
tion of about 70% human plasma albumin (Granger, 
2005). Using afﬁ  nity chromatography, the speciﬁ  c 
removal of 98%–99% of albumin (Greenough, 
2004; Fountoulakis, 2004) and detection of many 
lower abundance proteins (Pieper, 2003) from 
human plasma have been reported. However, this 
approach does not appears applicable to a large 
number of samples. Various depletion columns 
have also been tested and were shown to remove 
96%–99% of albumin from human serum samples 
(Björhall, 2005). The Multiple Afﬁ  nity Removal 
System (Agilent technologies), composed of bead-
ﬁ  xed antibodies, is one of the most successful 
devices that is designed to remove six to seven 
interfering major proteins from human plasma 
samples and three from mouse plasma samples. It 
reduces the total human serum protein mass by 
Table 1. Total protein amount and estimated albumin amount in plasma samples.
 Crude  plasma  SPE  UF  UF-SPE
Plasma sample volume (µL) 500  500  500  500
Eluates or ﬁ  ltrates volume (µL) -  800  2000  200
Total protein concentration in  59.40 ± 1.10  -  -  -
sample (mg/mL)
Total protein concentration in  -  13.86 ± 0.45*  0.68 ± 0.04*†  0.64 ± 0.01*†
eluates or ﬁ  ltrates (µg/mL)
Total amount of proteins in  29.70 ± 0.32  -  -  -
sample (µg)
Total amount of proteins in  -  11.09 ± 0.36*  1.36 ± 0.04*†  0.13 ± 0.01*†◘
eluates or ﬁ  ltrates (µg)
% protein depletion  -  62.65 ± 0.39  95.75 ± 0.04†  99.57 ± 0.01†◘
      
Estimated amount of albumin  13 ± 1  -  -  -
in sample (mg)
Estimated amount of albumin  -  7769 ± 518*  10 ± 1*†  <1*†◘
in eluates or ﬁ  ltrates (µg)
Estimated % albumin  -  42.1 ± 3.8  99.9 ± 0.1†  >99.9†◘
depletion
Crude plasma samples were compared to the eluates and ﬁ  ltrates obtained through three plasma sample preparation protocols. See Figure 1 
legends for details regarding the SPE, UF and UF-SPE protocols. Total amount of proteins in crude plasma samples, UF ﬁ  ltrates and SPE and 
UF-SPE eluates were calculated from total protein concentrations determined by a BCA protein assay kit. Estimated amount of albumin in crude 
plasma samples, UF ﬁ  ltrates and SPE and UF-SPE eluates were deduced from relative quantitation performed by UV absorbance using an 
Agilent 1100 series HPLC system (see Fig. 3 for calibration curve). Values are means ± SEM of 2–4 determinations per protocol. * signiﬁ  cantly 
different from crude plasma (p   0.02). † signiﬁ  cantly different from SPE (p   0.02). ◘ signiﬁ  cantly different from UF (p   0.02).392
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85% (Martosella), and provides an albumin deple-
tion rate  99% (Björhall, 2005; Brand, 2006). 
However, such a system does not allow to fraction-
ate simultaneously a high number of samples. Solid 
phase extraction and membrane ﬁ  ltration are other 
suitable methods to remove high abundance pro-
teins and better detect the low abundance plasma 
protein fraction (Tirumalai, 2003; Chernokalskaya, 
2004; Souverain, 2004; Koomen, 2005; Orvisky, 
2006; Ingvarsson, 2006). To better characterize 
these latter methods, we evaluated the % albumin 
depletion that can be obtained by the SPE, UF and 
UF-SPE protocols that are presented here. To this 
end, we used various concentrations of aqueous 
HSA to construct calibration curves, and UV 
absorbance to detect the albumin corresponding 
signals (Fig. 3). Hence, we show here that the 
estimated amount of albumin present in the various 
samples was lowered in a gradual manner accord-
ing to the protocol considered (Table 1), being 
signiﬁ  cantly reduced by SPE compared to crude 
plasma (1.7-fold; p = 0.0198), by UF compared to 
SPE (728.5-fold; p = 0.0044) and by UF-SPE 
compared to UF (761.1-fold; p = 0.0106). The use 
of membrane ﬁ  ltration, alone or in combination 
with SPE, then provide a signiﬁ  cantly more efﬁ  -
cient (∼2.4 times more; p = 0.0044) albumin deple-
tion ( 99.9%) than the use of SPE sorbent alone 
(42.1%). The combination of UF and SPE depleted 
significantly more albumin than UF alone 
(p = 0.0106). In the SPE protocol we decided to 
distribute the sample to four wells of the Oasis
® 
HLB extraction plate to limit overcharge. The poor 
albumin depletion capacity of this protocol may 
be due, in part, to the fact that four wells are not 
enough. Indeed, about 50 wells should have been 
used for an unique sample to avoid any overcharge, 
what we considered incompatible with high 
throughput analyses. From these results, membrane 
ﬁ  ltration combined with SPE appear to deplete 
albumin from plasma samples as efﬁ  ciently as 
more speciﬁ  c techniques like the Agilent Multiple 
Afﬁ  nity Removal System (see above). Disappear-
ance of the albumin band in the SDS-PAGE 
analysis conﬁ  rm the high efﬁ  ciency of the UF and 
UF-SPE protocols in depleting albumin (lanes 5 
and 6 of the Coomassie blue stained gel, Fig. 2). 
These protocols have also the advantage to be suit-
able for high troughput analyses.
3.2. MALDI-TOF/MS analyses after 
the three plasma sample preparation 
protocols
SPE eluates, UF ﬁ  ltrates and UF-SPE eluates as well 
as washing solutions (SPE and UF-SPE) were ana-
lyzed by MALDI-TOF/MS using an Ultraflex 
instrument (Bruker Daltonics) operated in positive 
mode. Spectra were acquired both in the linear and 
reﬂ  ector modes. Mass spectra were all dominated 
by an intense signal at ∼1740 m/z (Fig. 4). Peak 
intensities were much higher after the UF-SPE 
protocol with more peaks detected, thus indicating 
a higher sensibility of detection after this protocol. 
Table 2 summarizes the numbers of peaks that were 
detected using the three fractionation protocols, in 
a single experiment or when considering duplicate 
experiments. Hence, the maximum number of peaks 
which were detected after the UF-SPE protocol in 
a single experiment (N1 = 77 peaks, Table 2) was 
Figure 2. 1-D SDS-PAGE analysis of crude plasma (lane 2), commercially prepared HSA (lane 3), SPE eluate (lane 4), UF ﬁ  ltrate (lane 5), 
and UF-SPE eluate (lane 6). Molecular weight markers (6.5–205-kDa) were electrophoresed in lanes 1 and 7. 20 µg total protein was applied 
per lane and visualized by coomassie blue staining. The albumin band is shown. See Figure 1 legends for details regarding the SPE, UF 
and UF-SPE protocols.393
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higher than after the UF (1.3–1.4-fold) and SPE 
(1.7–3.8-fold) protocols. In line with these results, 
about 20–50 peptide peaks were observed for exam-
ple 1) in a single MALDI-TOF/MS mass spectrum 
from human serum (1 mL) using ultraﬁ  ltration and 
ZipTip C18 desalting as the sample preparation pro-
tocol (Chernokalskaya, 2004), and 2) in a SELDI-
TOF/MS analysis of human serum (20 µL) after 
fractionation using anion exchange beads in a 
96-well format (Solassol, 2005).
In the current study, with respect to the repro-
ducibility of the 4 repeated spots in each sample 
in a single experiment, the calculated CVs for all 
peaks were below 20%–35% in all samples. Such 
CV values are in line with commonly observed 
CVs, that are generally calculated for few selected 
peaks in the literature (Zhang, 2004; Baumann, 
2005; Orvisky, 2006). In the present study, CV 
values were calculated on all peaks, what support 
strongly the good reproducibility of the three 
protocols. Consequently, we included all spectra 
in duplicate experiment comparisons. To perform 
these comparisons, we set the threshold of accept-
able CV between duplicate experiments at 35%. 
Consequently, 70%–90% of the N1 peaks (see 
Table 2) were considered to be detected in a repro-
ducible manner between duplicate experiments in 
linear mode and 55%–80% in reﬂ  ector mode. 
These percentages, which correspond to the N2 
peaks mentioned in Table 2, conﬁ  rm the good 
reproducibility of the three protocols, the UF and 
UF-SPE protocols providing the most reproducible 
data. The majority of the N2 peaks (43%–57% in 
linear mode and 77%–82% in reﬂ  ector mode) were 
found in the low mass range (1000–2300 m/z in 
linear mode and 800–2000 m/z in reﬂ  ector mode). 
32%–36% (linear mode) and 18%–23% (reﬂ  ector 
mode) of the N2 peaks were found in the medium 
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Figure 3. Representative UV-chromatograms of 50 µL of either diluted or concentrated samples. See Figure 1 legends for details regarding 
the SPE, UF and UF-SPE protocols. UV absorbance detection was set at 214 nm. A calibration curve was constructed using HSA for the 
determination of albumin (Alb) quantity in crude plasma, SPE eluates, UF ﬁ  ltrates and UF-SPE eluates. Error bars indicate the relative 
standard error for each sample run in duplicate. Full range and expanded chromatograms of all four samples are shown at the same scale. 
Integrated areas and retention time of albumin are given. UV peaks corresponding to haemoglobin (Hb) are also shown.394
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mass range (2300–3700 m/z in linear mode and 
2000–3000 m/z in reflector), the remaining 
4% –12% of the N2 peaks detected with the linear 
mode ranging from 3700 to 6000 m/z. Moreover, 
reproducibility was always better in the low mass 
range, either in linear or reﬂ  ector mode. When analyz-
ing also washing solutions from the SPE and UF-SPE 
protocols, some more peaks below 3600 m/z can be 
detected (see N3 in Table 2) with a CV between dupli-
cates that was, for 60%–100% of them, less than 30%. 
Enrichment of small peptides were then favoured by 
all these protocols and their detection has been 
achieved with great reproducibility.
Figure 5 compares the number of peaks that 
were speciﬁ  cally detected after a given protocol or 
just as well after more than a protocol. The UF and 
UF-SPE protocols bring many more informations 
than the SPE protocol. In addition to the 27 (linear 
mode) and 22 (reﬂ  ector mode) peaks that were 
detected after both the UF and UF-SPE protocols, 
23 (linear mode) and 34 (reﬂ  ector mode) supple-
mentary peaks have been detected speciﬁ  cally after 
the UF in comparison to the UF-SPE protocol. 26 
(linear mode) and 33 (reﬂ  ector mode) supplemen-
tary peaks have also been detected speciﬁ  cally after 
the UF-SPE in comparison to the UF protocol. As 
they bring a rather equivalent amount of speciﬁ  c 
informations, the UF and UF-SPE protocols there-
fore constitute complementary approaches to detect 
a maximum of endogenous plasma peptides.
As a consequence of the MALDI ionization 
procedure which results mostly in singly charged 
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Figure 4. Representative examples of the MALDI-TOF/MS spectra obtained after plasma fractionation by the SPE, UF and UF-SPE proto-
cols. See Figure 1 legends for details regarding these protocols. The molecular weight calculations (m/z values) and relative intensities are 
shown along the x- and y-axis, respectively. SPE eluates, UF ﬁ  ltrates, and UF-SPE eluates were analyzed using an Ultraﬂ  ex instrument 
(Bruker Daltonics) operated in positive mode. Spectra were acquired both in the linear (left panel) and reﬂ  ector (right panel) modes.
Table 2. MALDI-TOF/MS analyses of plasma samples processed by the SPE, UF, and UF-SPE protocols.
 Linear  mode  Reﬂ  ector mode
  SPE UF  UF-SPE  SPE UF  UF-SPE
Number of peaks (N1)  20 55 77  54 70  93
CV (%)   33   25   24   20   35   32
Number of peaks (N2)  14 50 53  30 56  55
Number of peaks (N3)  6 -  14  6 - 24
Three plasma sample preparation protocols were compared. See Figure 1 legends for details regarding the SPE, UF and UF-SPE protocols. 
MALDI-TOF/MS analyses were performed in positive mode using an Ultraﬂ  ex instrument (Bruker Daltonics). Spectra were acquired both in 
the reﬂ  ector and linear modes. N1 is the maximal number of peaks detected in a single experiment in SPE eluates, UF ﬁ  ltrates and UF-SPE 
eluates. N2 is the number of peaks detected in SPE eluates, UF ﬁ  ltrates and UF-SPE eluates with a CV less than 35% between duplicate 
experiments. N3 is the number of supplementary peaks that could be analyzed if considering also washing solutions. CV corresponds to 
calculated coefﬁ  cient of variations of all peak intensities normalized by global intensity of the corresponding spectrum in a single experiment. 
Peak numbers were deduced from annotated spectra using the FlexAnalysis software (Version 2.2, Bruker Daltonics) with a signal-to noise 
ratio >20 and >3 in linear and reﬂ  ector mode, respectively.395
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molecules, MALDI-MS spectra are easier to 
interpret and compare than those from ESI-MS. 
Therefore, LC MALDI-TOF/MS combination is 
well-adapted for peptide analysis of complex 
mixtures such as body ﬂ  uids (Clynen 2003). Because 
MALDI-TOF/MS spectra acquired from the UF-
SPE protocol provided numerous peak detections 
with greater peak intensities than the two other 
protocols, we further fractionated UF-SPE eluates 
using a microLC system. Following microcollect, 
a total of 460 (linear mode, up to 6100 m/z) and 388 
(reﬂ  ectror mode, up to 3900 m/z) peptide peaks were 
then detected in eight different fractions by MALDI-
TOF/MS (Fig. 5). About 64% (linear mode) and 
94% (reﬂ  ector mode) of these signals were below 
3000 Da. Reproducibility of these detections was 
estimated by calculation of a CV for approximately 
half of these signals, that were randomly selected. 
Between duplicate experiments, mean CV values 
were 31% and 34% for data acquired in linear and 
reﬂ  ector mode, respectively. Hence, by reducing the 
complexity of samples, microLC fractionation 
greatly improved the number of signals detected in 
a reproducible manner, in comparison to UF-SPE 
alone (4–6 times, Fig. 5). Such results are in accord-
ance with previous data showing that, independently 
of sample volumes, hundreds of peptides can be 
detected if sample preparation protocols are made 
up with chromatographic steps, in combination with 
various other fractionation techniques (Table 3). 
Moreover, ultraﬁ  ltration is always associated with 
improved detection of low molecular weight signals; 
the lower the MWCO, the lower the mass range of 
peak detection.
3.3. LOD and peptide recovery after 
the UF-SPE protocol
Spiked peptide quantities in plasma and UF-SPE 
eluates (500–10000 fmol) correspond to concentra-
tions of 1–20 nmol/L and 2.5–50 nmol/L, respec-
tively. After UF-SPE and subsequent microLC 
fractionation, 19 fractions of 32 µl were obtained 
per sample. Each fraction was then concentrated to 
10 µL, and analyzed by MALDI-TOF/MS. Spiked 
peptides were detected in eight different fractions. 
The lowest detected quantities for each peptide 
ranged from 0.5–5 pmoles. Such quantities corre-
spond to spiked concentrations of 1–10 fmol/µL 
prior to ultraﬁ  ltration (S1 in Table 4). We were then 
able to detect peptides whose spiked quantity rep-
resented, by weight, approximately 10
–6% of total 
plasma proteins in the initial 500 µL of sample.
In a previous work, determination of LOD has 
been performed after fractionation of plasma sam-
ples by ultraﬁ  ltration and reverse phase chroma-
tography (Tammen, 2005a). In this latter study, the 
lowest detected concentration was for example 
50 pM for ACTH18–39 and substance P, which cor-
respond to a LOD 20–200 times less than found 
here. This could be due to the fact that we fraction-
ated a volume of plasma 1.5 times less. Apart from 
the use of different ultraﬁ  ltration devices, we also 
introduced a complementary step of SPE, which 
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could remove an additional amount of materials in 
comparison to ultraﬁ  ltration alone. Moreover, we 
only collected 19 fractions by micoLC whereas 
Tammen et al. collected 96 of them (Tammen, 
2005a), thus all the more reducing sample 
complexity. Although SPE is probably the more 
limiting step of our protocol for LOD to correspond 
to peptides in concentrations relevant for biology 
and medicine, it has the advantages of strongly 
concentrating samples and of allowing high 
throughput analyses. This is obviously very impor-
tant in order to be able thereafter to inject the 
totality of the fractionated samples on a nanoLC/
MS/MS system with the aim of identifying the 
separated molecules, what is essential for any 
differential analysis in the ﬁ  eld of clinical and 
functional proteomics. Improved LOD to detect 
peptides representing less than 10
–7–10
–8% of total 
plasma proteins could then be obtained in the future 
by fractionating a higher initial volume of plasma, 
testing other SPE sorbents and multiplying the 
number of collected fractions. Nevertheless, the 
larger the number of fractions, the more the pro-
tocol will be incompatible with high throughput 
analyses.
In the same previous work of Tammen et al. 
determination of peptide recovery was also 
performed after fractionation of plasma samples, 
but not with the same mixture of spiked peptides 
(Tammen, 2005a). Only one peptide below 3000 Da 
(substance P) was spiked for recovery determina-
tion. In their conditions and as measured by ELISA, 
Table 3. Summary of serum and/or plasma peptide detections and identiﬁ  cations in the literature.
 Fractionation  protocol
Reference Plasma  UF  SPE  Chromatography  Other  N° of peaks detected
 ( µL) (MWCO)
Baumann, 2005  5  -  no  C3, C8 and C18  -  Hundreds ( 10 kDa)
       magnetic  beads
Orvisky, 2006  15  10–50 kDa  no  C8 magnetic SELDI  Hundreds  ( 5 kDa)
       beads
Koomen, 2005  20  -  yes  RP-C 18 LC   -  Hundreds ( 5.5 kDa)
Zheng, 2006  500  10 kDa  no  RP-C 18 LC   ZipTip C18  Hundreds ( 3.5 kDa)
         desalting
Merrell, 2004  1000  30 kDa  no  RP-POROS R1  Acetonitrile  Hundreds ( 2 kDa)
       Capillary  LC  precipitation
Tammen, 2005a,  1300  50 kDa  no  RP LC   -  Hundreds  ( 15 kDa)
2005b
In these six studies (see complete references in the text), peak detections were achieved through MALDI-TOF/MS and/or SELDI-TOF/MS 
analyses. UF, ultraﬁ  ltration.
Table 4. Spiked peptides with their monoisotopic masses, amino acid sequences, retention time, limit of detection 
and peptide signal recovery.
Name [M+H]
+ Sequence  Tr.  LOD  (fmol/µL)  Recovery
     (min.)  S1  S2  (%)
Angiotensin II  1046.54  DRVYIHPF  18.3  10  5  89–100
Angiotensin I  1296.68  DRVYIHPFHL  21.8  1  2.5  11–50
Substance P  1347.74  RPKPQQFFGLM-NH2  22.9  1  2.5  5–50
Bombesin 1619.82  p-EQRLGNQWAVGHLM-NH2  21.6  10  5  9–12
ACTH18–39 2465.20  RPVKVYPNGAEDESAEAFPLEF  24.0  10  25  8–33
Somatostatin 28  3147.47  SANSNPAMAPRERKAGCKNFFWKTFTSC  23.2  -  25  -
Various quantities of peptides from a commercial mixture were spiked 1) directly in the crude plasma before its entering in the UF-SPE 
protocol (S1), and 2) in the UF-SPE eluates (S2). Before MALDI-TOF/MS analysis, a microLC fractionation was performed. See Figure 1 
legends for details regarding the UF-SPE protocol. MALDI-TOF/MS analyses were performed in positive mode using an Ultraﬂ  ex instrument 
(Bruker Daltonics). Limit of detection (LOD) and peptide signal recovery for each spiked concentrations were determined from TIC-normal-
ized intensities, using the FlexAnalysis software (Version 2.2, Bruker Daltonics). Retention times (Tr.) of standard peptides were determined 
in control experiments without plasma.397
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it was shown that the use of membrane with a 
10 kDa MWCO allows a recovery of about 90% 
for substance P, and only 40% for osteocalcin, a 
protein of about 6 kDa. The main objective beyond 
biological sample fractionation, is to render pos-
sible mass spectrometry-based high throughput 
differential analyses, i.e., by MALDI-TOF/MS 
proﬁ  ling. Therefore, we believe that it was impor-
tant to determine recovery of a given peptide in a 
fractionated but still complex matrix, by mass 
spectrometry and not by a more sensitive method 
like ELISA. In other words, our aim was not to 
deﬁ  ne exactly peptide recoveries, but rather to 
estimate MALDI-TOF/MS signal recovery of 
spiked peptides. Although it is known that signal 
intensity of a given molecule obtained in a MALDI-
TOF/MS analysis is not strictly dependent on the 
molecule concentration, it is commonly observed 
that the signal intensity increases as the amount of 
molecule deposited on the MALDI target is 
increased. Such a characteristic notably provides 
a basis for proﬁ  ling approaches in the ﬁ  eld of 
biomarker research (Marshall, 2003; Linke, 2004; 
Tammen, 2005b; Baumann, 2005; Ebert, 2006; 
Orvisky, 2006). Indeed, a good linear correlation 
was found here by plotting MALDI-TOF/MS 
intensities against the spiked quantities (angi-
otensin I, r² = 0.980; substance P, r² = 0.995; 
bombesin, r² = 0.992). We compared spiked peptide 
peak intensities between S1 (spiking of crude 
plasma) and S2 (spiking of UF-SPE eluates) in 
order to estimate the loss of signal attributable to 
fractionation steps (Fig. 1). Recoveries of signals 
from the spiked peptides varied between 5% to 
100% depending on both the peptide and spiked 
quantity (Table 4). As we did not used ELISA, but 
MALDI-TOF/MS data to assess signal recovery, 
it is not surprising that lesser recoveries were found 
here in the peptide range than in the work from 
Tammen et al. (Tammen, 2005a), for example for 
substance P. This could also be due to the different 
initial sample volume and ultraﬁ  ltration devices, 
additional SPE step and lower number of LC frac-
tions, as mentioned for LOD determinations (see 
above). Best recoveries were obtained for the 
smaller peptides. Such a dependence of recovery 
on the molecular size of the spiked peptide was 
also observed by Tammen et al. (Tammen, 2005a), 
and may be due to the membrane used. The char-
acteristics of the devices used should therefore be 
well known and taken into account in order to choose 
the fractionation method most adapted to a type of 
given sample and to the purpose of the study.
3.4. NanoLC-Chip/MS/MS analyses 
after the UF-SPE protocol
Even if hundreds of peptides can be detected (see 
above) using various sample preparation tech-
niques, only a few studies are also designed to the 
characterization of these detected peptides. More-
over, “low molecular weight plasma fraction” is a 
concept that should be considered cautiously. 
Numerous peptides are indeed detected but the 
corresponding identiﬁ  ed molecules are rather more 
or less small proteins ( 10–50 kDa) than actual 
endogenous peptides (Tirumalai, 2003; Harper, 
2004; Koomen, 2005; Zheng, 2006). Most of the 
studies aiming at the exploration of the “low 
molecular weight serum proteome” include a step 
of enzyme digestion. This is the case for example 
in the study of Harper et al. (Harper, 2004), which 
reports the identiﬁ  cation of 262 proteins using 
ultraﬁ  ltration, isoelectric focusing and mass spec-
trometry of 200 µL of serum, and in that of 
Tirumalai et al. (Tirumalai, 2003), which reports 
the identiﬁ  cation of 341 unique proteins using 
ultraﬁ  ltration of 10 µL of serum, SCX chromatog-
raphy and microcapillary LC-MS/MS. In these two 
latter studies, identiﬁ  ed proteins are referred to as 
belonging to the human “low molecular weight 
serum proteome” despite that less than 2–3 of these 
are below 3000 Da and less than 7–15 are below 
10000 Da. Some other peptides were found to 
originate from proteolytic fragments of several 
large proteins. Finally, only a few studies have 
allowed speciﬁ  c identiﬁ  cation of 1–2 small pro-
teins and/or peptides (Tammen, 2005b; Orvisky, 
2006).
Although actual low abundance plasma protein, 
namely leptin and ghrelin, as well as peptides such 
as bradykinin have already been detected and 
identiﬁ  ed by mass spectrometry (Rose, 2004), this 
was achieved through an industrial-scale approach 
requiring hundreds of ml of plasma and separation 
by chromatographic techniques into thousands of 
fractions. In this framework, other studies have 
identiﬁ  ed low abundance plasma molecules, but 
their workflows were not designed for high 
throughput and/or large screening. Using for exam-
ple a differential peptide display technique, insulin 
and C-peptide levels have been identiﬁ  ed by mass 398
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spectrometry as modulated by oral glucose 
challenge after extraction by membrane ﬁ  ltration 
and separation by liquid chromatography into 
96 fractions (Tammen, 2005b). An analytical 
method has also been developed for the quantita-
tion of insulin in blood samples using SPE and 
liquid chromatography (Darby, 2001). In the low 
concentrated peptide range, fast and simple proto-
cols reducing sample complexity from 5–1000 µl 
of serum or plasma have, to our knowledge, led to 
point out only ﬁ  brinopeptide A, which is an endog-
enous circulating plasma peptide commonly found 
in the ng/mL range (van Hulsteijn, 1982; Ravanat, 
1996), as a potential biomarker (Marshall, 2003; 
Chernokalskaya, 2004; Ebert, 2006; Orvisky, 
2006). In an effort to analyse the true plasma pep-
tidome, we decided to avoid any digestion step. 
Such a strategy was recently applied to the human 
“low molecular weight serum peptidome” analysis 
using ultraﬁ  ltration of 500 µL of serum and a 
hybrid ion trap-Fourier transform mass spectrom-
eter, and led to the identiﬁ  cation (MS/MS sequenc-
ing) with high conﬁ  dence of 61 proteins, with some 
that are highly abundant and have a molecular 
weight greater than 50 kDa (Zheng, 2006). In the 
current study, nanoLC-Chip/MS/MS analyses 
allowed determination of tens of peptide sequence 
tags, including the spiked peptides (not shown). In 
order to show that our UF-SPE protocol was as or 
even more efﬁ  cient than previously reported works 
when aiming at the characterization of low abun-
dance plasma peptides, we only present here high 
conﬁ  dence identiﬁ  cation of low abundant (repre-
senting ∼10
–6% of total plasma proteins, by weight) 
endogenous ﬁ  brinopeptides A and B (Table 5). 
Fibrinopeptides play a key role in haemostasis 
(Stegnar, 2004). Such molecules can then bring 
informations on cardiovascular diseases and 
metabolic-related disorders. In addition to be well-
adapted to peptide enrichment, the UF-SPE proto-
col is then also valuable for low abundance 
molecules detection and characterization. This is 
obviously a major advantage when searching 
biomarkers of various diseases in clinical pro-
teomic studies and/or aiming at getting further 
insights in various physiological processes. This 
protocol is moreover adapted to high throughput 
analyses, which constitute an obvious requisite for 
differential peptidomic approaches.
Apart from hormones or cytokines, the low 
molecular weight plasma fraction also consists of 
proteolytic fragments of high molecular weight 
proteins which may reﬂ  ect endogenous proteolytic 
activities that play critical roles in biological proc-
esses (Boire, 2005; Villanueva, 2006). As we did 
not digested our samples by trypsin, a signiﬁ  cant 
number of peptides having non-tryptic termini 
were observed. Indeed, plasma contains numerous 
proteases with a non-tryptic speciﬁ  city (Richter, 
1999). In that sense, our results are consistent with 
those of several previous studies, which identiﬁ  ed 
a large number of peptides with non-tryptic termini 
(Adkins, 2002; Tirumalai, 2003; Zheng, 2006). As 
already observed in a previous study (Zheng, 
2006), we identiﬁ  ed several peptides that were 
derived from the same protein/peptide sequence. 
This was for example the case for ﬁ  brinopeptides 
A and B, the peptides corresponding to their 
sequence being progressively cleaved at the 
N- and/or C-termini (Table 5). Cleavages were 
observed at various residues. Such a result conﬁ  rm 
that endogenous proteases are involved in the 
generation of plasma low molecular weight pro-
teome and peptidome. However, since certain 
proteins did not exhibit such proteolytic frag-
ments, it is expected that proteases activities are 
rather speciﬁ  c, and the resulting peptides may then 
provide characterization of a given pathophysio-
logical state.
In the work of Zheng et al. (Zheng, 2006), some 
ions with a molecular weight of 3500–7500 Da 
were seen in the full MS scan using a LTQ-FTMS, 
but almost none of these were identiﬁ  ed by current 
commercial software such as SEQUEST. Two pos-
sible reasons for this were ﬁ  rst that a software like 
SEQUEST has difﬁ  culty interpreting CID spec-
trum from ions with a charge state of 4 or higher 
(no guidance for proper probability or Xcorr cut 
off), and second that larger peptides have a greater 
potential for being post-translationally modiﬁ  ed, 
which would also interfere with database identiﬁ  -
cations. The same reasons can be at the origin of 
lack of identiﬁ  cations of some MS-detected ions 
in our study, despite good MS/MS quality. To 
perform MS/MS data interpretation, we set the 
mass tolerance at 0.25 Da, which may be of insuf-
ﬁ  cient precision. Indeed, improving this mass 
tolerance to 0.0 Da by using for example an ion 
trap-Fourier transform mass spectrometer has 
proven to lead to numerous identifications as 
obtained in a previous study exploring endogenous 
human serum peptidome (Zheng, 2006). It could 
also be that the corresponding protein and/or pep-
tide is absent of protein databases, for example if 399
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the peptide sequence tag do not correspond to any 
proteolytic fragment or if no protein precursor is 
known. Finally, it is possible that too short 
sequences may impair identiﬁ  cations using the 
BLAST programs.
Conclusion
In this study, we developed simple protocols of 
plasma sample prefractionation that are adapted 
for high throughput analyses since quite all steps 
were automatised and would be capable of process-
ing up to 96 samples in parallel. An efﬁ  cient sepa-
ration of low and high abundance molecules was 
obtained as illustrated by the estimation of a  99% 
albumin depletion, and by enrichment of more than 
450 peptides ( 3000 m/z). Details on MADI-
TOF/MS spectra show good reproducibility 
(CV   30%–35%) of detections through frac-
tionation protocols combining ultraﬁ  ltration and 
SPE. MALDI-TOF/MS-determined LOD, as low 
as 1 fmol/µL for spiked peptides representing ∼10
−6% 
of total proteins by weight, and signal recovery of 
spiked peptides were shown to depend on the 
peptide and concentration. In addition to being 
focused on the enrichment of peptides below 
3000 Da we also had an effort to get sequence 
informations. By MS/MS sequencing, we were 
able to identify spiked peptides and also low abun-
dance peptides, namely ﬁ  brinopeptides A and B, 
as efﬁ  ciently or even more than other studies. Such 
peptides can bring important informations regard-
ing cardiovascular diseases and metabolic related 
disorders. Altered patterns of progressively cleaved 
peptides from a single protein could also be of 
valuable importance in the characterization of a 
given pathophysiological state.
In an attempt to explore, in the future, the low 
molecular weight plasma fraction, the use of a 
fractionation protocol like UF-SPE therefore would 
be of particular interest in the context of differen-
tial proﬁ  ling analyses. To detect and characterize 
more and more low abundance molecules, such a 
protocol would also be developed to fractionate 
higher initial plasma volumes.
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Table 5. Identiﬁ  cation of rat plasma ﬁ  brinopeptides A and B using a nanoChip-LC/MS/MS instrument and the 
NCBInr database.
ID  AC  Peptide  Observed ion  Charge  Ion  Peptide sequence
   mass  [M]  [M+nH]
n+   score 
Fibrinopeptide A  650771P  1105,56  553,79  2+  38  EFIEAGGDIR
   1192,59  597,30  2+  62  SEFIEAGGDIR
   1293,64  647,83  2+  73  TSEFIEAGGDIR
   1394,69  698,35  2+  96  TTSEFIEAGGDIR
   1451,72  726,87  2+  81  GTTSEFIEAGGDIR
   1552,76  777,39  2+  103  TGTTSEFIEAGGDIR
   1667,83  834,92  2+  108  DTGTTSEFIEAGGDIR
   1738,86  870,44  2+  144  ADTGTTSEFIEAGGDIR
   1738,88  580,63  3+  23  ADTGTTSEFIEAGGDIR
   1582,59  792,30  2+  56  ADTGTTSEFIEAGGDI
Fibrinopeptide B  650771AE  1061,54  531,78  2+  20  DSDKVDLSIA
   1079,54  540,78  2+  37  TTDSDKVDLS
   1150,57  576,29  2+  40  ATTDSDKVDLS
   1162,58  582,30  2+  46  TDSDKVDLSIA
   1318,66  440,56  3+  35  TDSDKVDLSIAR
   1318,66  660,34  2+  46  TDSDKVDLSIAR
   1334,66  668,34  2+  23  ATTDSDKVDLSIA
   1419,70  474,24  3+  50  TTDSDKVDLSIAR
   1419,70  710,86  2+  101  TTDSDKVDLSIAR
   1490,74  746,38  2+  105  ATTDSDKVDLSIAR
Peptide sequences were observed in MASCOT results (ion scores are given in the table), and conﬁ  rmed by de novo sequencing (in bold) 
using the PEAKS Studio 3.0 software (Bioinformatics Solutions Inc.). Blast E values were commonly  1 ( 0.2 for 75% of the searches).400
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Abbreviations
SPE: solid phase extraction; UF: ultraﬁ  ltration; 
UF-SPE: combination of ultraﬁ  ltration and solid 
phase extraction; HSA: human serum albumin; 
CV: coefﬁ  cient of variation; LOD: limit of detec-
tion; Tr. retention time.
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